Actively Recruiting
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Led by Novo Nordisk A/S · Updated on 2026-01-23
75
Participants Needed
1
Research Sites
36 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
CONDITIONS
Official Title
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently on maintenance treatment with liraglutide 3.0 mg for at least 5 days, oral semaglutide 25 mg for at least 5 weeks, or semaglutide 2.4 mg for at least 5 weeks before screening.
You will not qualify if you...
- Previous participation or rescreening in this study.
- Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential without adequate contraception.
- Participation in any other interventional clinical study.
- Exposure to investigational drugs except required GLP-1 treatments within 30 days or 5 half-lives before screening.
- Any condition that may risk safety or compliance.
- Expected lifestyle changes during the study.
- Investigator, site staff, or their relatives involved in the study.
- Mental incapacity, language barriers, or unwillingness to follow the protocol.
- Significant gastrointestinal disorders affecting drug or nutrient absorption.
- History of major stomach or esophagus surgery affecting absorption or presence of gastrointestinal implants.
- Severe kidney impairment with eGFR below 30 ml/min/1.73 m².
- Current treatment with insulin or secretagogues causing hypoglycemia during fasting.
- History of ketoacidosis.
- Clinically significant gastroparesis, hiatal hernia, or severe gastroesophageal reflux with daily symptoms.
- Use of medications affecting stomach motility.
- Inability to lie on the right side for stomach ultrasound.
- Unusual eating habits, special diets, or unwillingness to eat study meals as declared or recorded.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Altasciences Clinical LA, Inc.
Cypress, California, United States, 90630
Actively Recruiting
Research Team
N
Novo Nordisk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here